Tags : IPATential150 study

Roche to Present its Oncology Portfolio at the ESMO Virtual

Shots: Roche highlights data from three P-III studies across the Tecentriq (atezolizumab) TNBC programme, CNS efficacy data from integrated analyses of the pivotal Rozlytrek (entrectinib) clinical development program, and the data from the registrational P-I/II ARROW trial assessing Gavreto (pralsetinib) for RET-mutant MTC patients Data from the P-III IPATential150 study in mCRPC patients and whose […]Read More